Spontaneous splenic rupture in patient with metastatic melanoma treated with vemurafenib

Elisa Castellani¹, Piero Covarelli¹, Carlo Boselli¹, Roberto Cirocchi², Antonio Rulli¹, Francesco Barberini¹, Daniela Caracappa¹, Carla Cini¹, Jacopo Desiderio²*, Gloria Burini¹ and Giuseppe Noya¹

Abstract

Background: BRAF inhibitors such as vemurafenib are a new family of biological drugs, recently available to treat metastatic malignant melanoma.

Methods: We present the case of a 38-year-old man affected by metastatic melanoma who had been under treatment with vemurafenib for a few days. The patient suffered from sudden onset of abdominal pain due to intra-abdominal hemorrhage with profuse hemoperitoneum. An emergency abdominal sonography confirmed the clinical suspicion of a splenic rupture.

Results: The intraoperative finding was hemoperitoneum due to splenic two-step rupture and splenectomy was therefore performed. Histopathology confirmed splenic hematoma and capsule laceration, in the absence of metastasis.

Conclusions: This report describes the occurrence of a previously unreported adverse event in a patient with stage IV melanoma receiving vemurafenib.

Keywords: Spontaneous splenic rupture, Melanoma, BRAF, Vemurafenib

Background

Atraumatic splenic rupture (ASR) is a rare pathology that can be idiopathic (7%) or pathological (93%) in nature [1]. While in the first group there are no abnormal histopathological findings, in the second one several etiological factors can be identified, including neoplastic (30%), infectious (27%), inflammatory non-infectious (20%), drug- or treatment-related (9%), and mechanical disorders (6%) [1].

ASR is an often unrecognized and potentially fatal cause of acute abdomen development; it should be routinely considered in the differential diagnosis of such pathology and when present promptly managed, at best with laparotomic approach [2]. The commonest causes of this rare pathology are: malignant hematological disorders (16%) such as acute leukemia and non-Hodgkin’s lymphoma; viral infections (15%) as infectious mononucleosis and cytomegalovirus infection; and local inflammatory and neoplastic disorders (11%) such as acute and chronic pancreatitis. Splenomegaly is a common feature, affecting 55% of patients. There is a male gender prevalence of 2:1, with a mean age of 45 years, (median 45, range 18–86 years). The overall ASR-related mortality rate is 12% [1].

Although, nowadays, the laparoscopic approach is the routine procedure for various diseases requiring elective splenectomy, in emergency cases laparotomy still retains its effectiveness, first and foremost with regard to patients with unstable hemodynamic conditions.

Case presentation

In September 2011, a 38-year-old man was admitted in urgency regimen to our department because of a moderate left flank pain starting 6 h before hospital admission. The patient also presented vomiting and diffuse abdominal tenderness. Minor discomfort had been present in the left flank for a few days. The patient had a 3-year history of melanoma, starting in November 2008 with the removal of a forehead superficial spreading melanoma, 7 mm in diameter, Breslow thickness being...
0.44 mm, with discrete lymphocytic infiltrate mainly in the surrounding tissue, without ulceration or regression. Only radicalization of local excision and follow-up were required according to the initial staging; sentinel node biopsy was therefore not performed.

In June 2011, 31 months after primary tumor excision, and 3 months before the episode of acute abdominal pain, the patient underwent an emergency orchietomy because of the onset of acute scrotal swelling, with a pathologic diagnosis of metastatic melanoma to the testis (with an immunohistochemical profile positive for HMB-45, S-100, MART-1, and negative for pancytokeratin and inhibin). At that time, PET and CT scans showed several possible metastases, in soft tissues, gastro-intestinal tract, lungs, and brain; biopsies of masseter muscle, stomach, and duodenum confirmed the diagnosis.

The patient, after testing positive on screening for MO255515 protein, was recruited to an experimental protocol using BRAF inhibitors and thus received a first cycle of therapy with vemurafenib at an oral dose of 960 mg twice daily. He did not undergo combined therapy with cytotoxic drugs, but received vemurafenib alone. Such experimental protocol was part of a compassionate care strategy and foresaw specific exclusion criteria, such as the presence of second malignancies, renal failure and diabetes mellitus, co-morbidities that our patient did not have. The acute abdominal event occurred 12 days after starting treatment, when the patient had assumed a total cumulative dose of about 23 g.

On admission the patient was pale and suffering, and his vital parameters were as follows: oxygen saturation 100%; heart rate 90 bpm, temperature 36.5°C, blood pressure 90/45 mmHg. His medical history was otherwise negative, and no trauma or accident had been previously reported. An abdominal examination showed diffuse pain and peritoneal fluid was noticed at percussion; a nasogastric tube was placed without detecting gastric retention and a urinary catheterization showed oliguria. A complete blood count showed moderate leukocytosis (13.67 WBC x10³) and anemia (RBC 3.42 x10⁶, Hb 10.4 g/dL, Ht 30.8%). An immediate abdominal sonography confirmed the clinical suspicion of spontaneous rupture of the spleen with massive hemoperitoneum (Figure 1). The patient immediately underwent an emergency laparotomy. Intraoperative findings have been massive hemoperitoneum (approximately 3 L of blood and coagula) due to a two-step rupture of the spleen, with subsequent subcapsular hematoma and complete decortication, that required a splenectomy; splenic size was within the normal range (Figure 2). Some suspected metastatic nodes were removed from the great omentum; histopathology confirmed the metastatic nature of the omental nodes while the spleen was decorticated in the absence of metastases.
Discussions

Melanoma is the deadliest form of skin cancer; its incidence has been increasing continuously and over 40,000 people die of this disease each year worldwide [3]. The estimated number of new cases of melanoma in 2010 in the United States was 68,130, of which 57% affected males and 43% females. In the same period, the estimated deaths caused by this pathology were 8,700 (65% males and 35% females) [4].

The disease presents genetically and clinically distinct subgroups that could indicate the need of patient-specific management strategies [5]. For example, head and neck mucosal malignant melanomas behave much more aggressively than limb or trunk tumors and their prognostic markers have not yet been fully elucidated [6]. The majority of metastases appears within 3 years from the diagnosis of primary melanoma [7]. Primary melanoma metastasizes most frequently to lymph nodes and lungs (about 70%). Less common sites of metastasis are liver (58%), brain (54%), bones (48%), adrenal glands (46%), and gastrointestinal tract (43%). Among this group, small intestine and spleen are affected in 36.5% and 30.6% of cases, respectively [7]. The 1-year survival rate for patients with systemic metastasis from cutaneous melanoma ranged from 40% to 60% in the American Joint Committee on Cancer (AJCC) Melanoma Staging Database [8]. Our patient had a stage IV melanoma, and, therefore, an extremely poor prognosis with median survival ranging from 6 to 18 months after diagnosis [9] and a 5-year survival rate of less than 5% [10-12].

Melanoma treatment has experienced a rapid change in recent years through recent discoveries of target therapies and immunotherapeutic antibodies. With the continuous progress of research, prolonged therapeutic success may be achieved through the tailored use of molecular markers and immunotherapies in sequential or combinatorial methods [13,14]. Advanced melanomas often have multiple genetic defects affecting several biochemical pathways. Somatic point mutations in RAF occur in approximately 8% of human tumors, most frequently in melanoma, colorectal, and thyroid cancers [4,14,15]. The targeting of this single oncogenic alteration with specific inhibitory nucleic acids or chemical RAF inhibitors in melanoma cell lines showed growth arrest and induction of apoptosis [16,17].

Although melanoma metastases have been found to contain thousands of mutations, the V600E BRAF mutation is clearly a driver of the neoplastic phenotype and is present in approximately 50% of melanomas [5,18]. The discovery of activating mutations (V600E) in the BRAF kinase encouraged the development of compounds to inhibit aberrant BRAF activity [5]. Vemurafenib (also known as PLX4032, RG7204, or RO5185426) marketed as Zelboraf is a BRAF enzyme inhibitor developed by Plexxikon (Berkeley, CA, USA, now part of the Daiichi Sankyo Group) and Roche [15]. PLX4032 was recently observed to increase median overall survival in metastatic melanoma. However, resistance through up-regulation of receptors or by activating mutations in oncogenic signaling and alternative enzymes is proving to be an emerging problem [3]. The comparison between vemurafenib and conventional treatment with dacarbazine led to encouraging results regarding 6-month survival, which was 84% in the vemurafenib group and 64% in the dacarbazine group. The risk of either death or disease progression was also reduced in the vemurafenib group [9]. In summary, these studies reveal that, for the first time, several immunotherapeutic and targeted agents are yielding some clinical responses and improvements in overall survival in patients with unresectable stage III and IV melanoma [3]. In patients with metastatic melanoma featuring BRAF V600E mutation, phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% [9].

Selective BRAF inhibitors show good tolerability with infrequent severe toxicities. Among the common adverse events associated with vemurafenib are skin changes 50% to 70% (rash, alopecia, keratoacanthoma or squamous-cell carcinoma, photosensitivity), fatigue, and arthralgia 30% to 50%, diarrhea 10% to 30%, and nausea 10% to 20% [16]. About 15% to 30% of patients treated with type I BRAF inhibitors, such as vemurafenib, develop squamous-cell carcinomas and keratoacanthomas. These non-melanoma skin cancers are not deadly, but they can become dangerous, when they rarely become metastatic [19]. Squamous cell tumors from patients treated with BRAF inhibitors have a distinct mutational profile. A higher frequency of activating RAS mutations was found in tumors from patients treated with vemurafenib (about 60%) vs. sporadic cases (range between 3% and 30%) [20]. Vemurafenib alone does not increase the number of tumors; it just decreases their latency by promoting pre-existent mutations. This is evidenced by the early appearance of lesions (within the first few weeks) after assumption of vemurafenib, and only in a subset of patients [21]. Therefore, testing the RAS status should be useful in patients who undergo treatment with BRAF inhibitors. Assuming that concomitant administration of MEK inhibitors can stop vemurafenib-induced acceleration of tumor growth in patients with RAS mutation, it may be possible to develop a new generation of BRAF inhibitors [22-24].

Another emerging problem is the resistance to BRAF inhibitors that develops within months [25].

Recent studies suggest that it could depend on tyrosine-kinase receptors (like PDGFR and IGFR-1) [26,27]. Inhibitors of c-Kit and mitogen-activated protein
kinase (MEK) have also been found to act against melano-
nomas, and MEK inhibitors are now being examined as
a strategy to overcome BRAF inhibitor resistance [27].

ASR is uncommon but fatal if untreated. Its diagnosis
should not be missed or delayed because of low clinical
suspicion; in contrast it should be routinely considered
in the differential diagnosis of acute surgical abdomen
and of a wide range of medical conditions [28]. Various
hypotheses could be advanced concerning the possible
correlations between underlying disease, drug therapy,
and acute complications. The possibility that a link be-
tween cancer and spontaneous splenic rupture exists in
the absence of splenic metastasis or chemotherapy has
been suggested for a long time, and the reasons are to
be found in a hypercoagulable state secondary to the
underlying malignancy [29-32]. Furthermore, the possi-
bility of splenic rupture without a previous trauma in
patients under treatment for abdominal manifestations
of metastatic cancer has already been described, but me-
tastases were assumed to be the cause [33,34]. Another
possible cause might be found in alterations of angiogen-
esis pathways; BRAF V600E-dependent VEGF production
has been suggested as angiogenetic promoter mechan-
ism [35]. Oncogenic BRAF V600E mutation seems to
enhance the expression of several proangiogenic and pro-
Inflammatory molecules, including VEGF-A [36].
BRAF binds to and is downstream from the main effect-
ors of KRAS, whose activating mutations are believed
to support the chaotic tumor vascularity, by up-
regulating the transcription of several angiogenic indu-
cers, including VEGF-A [37]. This might have caused
splenic parenchyma fragility, resulting in a greater ten-
dency to a spontaneous or minor trauma-related rup-
ture; in fact, whether and to what measure BRAF
regulates and alters angiogenesis is still unclear.

Conclusions
As shown by clinical data, we can assume a relationship,
which is currently not verifiable, between the intake of
BRAF inhibitors and spontaneous rupture of the spleen;
also superficial venous thrombosis in the postoperative
course has been reported. With this report we intend
to comment on an unusual event, namely the spontaneous
rupture of the spleen occurred in a patient with stage IV
melanoma under treatment with vemurafenib, in the
absence of neoplastic involvement of the spleen, spleno-
megaly, or major alterations of coagulation.

Consent
Written informed consent was obtained from the patient
in publication of this manuscript and any accompany-
ing images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.

Abbreviations
AJCC: American Joint Committee on Cancer; ASR: Atraumatic Splenic
Rupture; BRAF: V-raf murine sarcoma viral oncogene homolog B1;
CT: Computer Tomography; Hb: Hemoglobin; HMB-45: Human Melanoma
Black; Ht: Hematocrit; IGFR-1: Insulin-like Growth Factor 1 (IGF-1) Receptor;
IL: International Units; LMMH: Low Molecular Weight Heparin; MATE-
1: Melanoma Antigen Recognized by T-cells; MEK: Mitogen-Activated protein
Kinase; PDGFR: Platelet-Derived Growth Factor (PDGF) Receptors;
PET: Positron Emission Tomography; RBC: Red Blood Cells; S-100: 100%
Soluble protein (in ammonium); WBC: White Blood Cells.

Competing interests
The authors state that none of the authors involved in the manuscript
preparation has any conflicts of interest regarding the manuscript itself,
neither financial nor moral conflicts. Furthermore, none of the authors
received support in the form of grants, equipment, and/or pharmaceutical
items.

Authors’ contributions
All authors contributed equally to this work, read, and approved the final
manuscript.

Author details
1Department of General and Oncologic Surgery, University of Perugia,
Perugia, Italy. 2Department of General Surgery, University of Perugia, St. Maria
Hospital, Via Tristani di Joannuccio, Terzi 05100, Italy.

Received: 20 February 2012 Accepted: 8 June 2012
Published: 30 July 2012

References
1. Renzulli P, Hostettler A, Schoepfer AM, Gloor B, Candinas D: Systematic
review of atypical splenic rupture. Br J Surg 2009, 96:1114–1121.
2. Rhee SJ, Sheena Y, Imber C: Spontaneous rupture of the spleen: a rare
but important differental of an acute abdomen. Am J Emerg Med 2008,
26:733.
3. Natarajan N, Telang S, Miller D, Chelsey J: Novel immunotherapeutic
agents and small molecule antagonists of signalling kinases for the
metastatic treatment of melanoma. Diugis 2011, 71:1233–1250.
4. Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin
2010, 60:277–300.
5. Vultur A, Villanueva J, Herlyn M: Targeting BRAF in advanced melanoma: a
first step toward manageable disease. Clin Cancer Res 2011, 17:1658–1663.
6. Kerr EH, Hameed O, Lewis JS Jr, Bartolucci AA, Wang D, Said-Al-Naief N:
Head and neck mucosal malignant melanoma: clinicopathologic
characteristics of a contemporary review of prognostic indicators. Int J Surg
Pathol 2012, 20:37–46.
7. Di Libero L, Sciascia V, Esposito D, Variale T, Santilli L: Surgical
management of metastases from cutaneous melanoma to the small
intestine and the spleen. Case reports and review of the literature. Ann Ital
Chir 2011, 82:233–238.
8. Balch CM, Genschewieft JD, Soong SJ, Thompson JT, Atkins MB, Byrd DR,
Buzaid AC, Cochran AJ, Colt DG, Ding S, Eggermont AM, Flaherty KT,
Gimotty PA, Kirkwood JM, Masters KM, Mihm MC Jr, Morton DL, Ross MI,
Sober AJ, Sondak VK: Final version of 2009 AJCC melanoma staging and
classification. J Clin Oncol 2009, 27:6199–6206.
9. Chapman PB, Hauschild A, Robert C, Sondak VK, Dummer R, Andreev A,
Ghobashy A, Demidkov I, Hess KR, Lao Y, Lebbe C, Sznol M, Ribas A,
Pardoll D, Hamid O, Kefford RF, Stupp R, Hausman-Frankforter M:
BRAF and MEK inhibition in melanoma: the combination is greater than
the sum of its parts. Ann Oncol 2011, 22:772–779.
10. Pollack LA, Li J, Berkowitz Z, Weir HK, Wu XC, Ajani UA, Ekwueme DU, Li C,
Pollack BP: Melanoma survival in the United States, 1992 to 2005. J Am
Oncol Acad Dermatol 2011, Suppl 1:78–86.
11. Hafner C: Therapie des metastasierten Melanoms mit BRAF-Inhibiteoren.
Hautarzt 2011, 62:696–698.
12. Rondelli F, Vedovato MC, Becattini C, Tomassini GM, Mesina S, Noya G,
Simonetti S, Covarelli P: Prognostic role of sentinel node biopsy in
patients with thick melanoma: a meta-analysis. J Eur Acad Dermatol
Venereol 2012, 26:5560–565.

http://www.wjso.com/content/10/1/155
Page 4 of 5
Castellani et al. World Journal of Surgical Oncology 2012, 10:155
13. Hamid O, Boasberg PD, Rosenthal K, O'Day SJ: Systemic treatment of metastatic melanoma: New approaches. J Surg Oncol 2011, 104:425–429.

14. Pratilas CA, Solt DB: Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response. Clin Cancer Res 2010, 16:3230–3234.

15. Bollag G, Hirth P, Tsi A, Zhang L, Ibrahim PN, Cho H, Spevak W, Zhang Y, Habets G, Burton EA, Wong B, Tsang G, West BL, Powell B, Shellooe R, Marimuthu A, Nguyen H, Zhan KY, Arts DR, Schlessinger J, Su F, Higgins B, Iyer R, D’Andrea K, Koehler A, Stumm M, Lin PS, Lee RJ, Griggi J, Puzanov I, et al: Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010, 467:598–599.

16. Arkenau HTF, Kefford R, Long GI: Targeting BRAF for patients with melanoma. Br J Cancer 2011, 104:392–398.

17. Calipel A, Lefevre G, Pourpounot C, Mouriaux F, Ychene A, Mascarelli F: Mutation of B-RAF in Human choroidal melanoma cells mediate cell proliferation and transformation through the MEK/ERK pathway. J Biol Chem 2003, 278:42409–42418.

18. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Walters S,MK, Edkins S, Clegg S, Teague J, Walters S, Pooler J, Taylor G, Todd J, Braithwaite I, Carter N, Chen K, Cooper C, Stephen S, et al: The mutations database: a knowledgebase for the human cancer mutations project. Nucleic Acids Res 2002, 31:254–257.

19. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur G, Somasundaram D, O’Byrne PJ, Lee RJ, Griggi JF, Nolop K: Inhibition of mutant, activated BRAF in metastatic melanoma. N Engl J Med 2010, 363:809–819.

20. Oberholzer PA, Kee D, D’Aniulcz P, Sucker A, Kamsukom N, Jones R, Roden C, Chalk CJ, Airdie K, Palescandolo E, Piras A, Maccone IL, Robert C, Hofbauer GF, McArthur GA, Schadendorf D, Garaway LA: RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol 2012, 30:316–321.

21. Su F, Vios A, Milagre C, Trunzer K, Bollag G, Spleiss O, Reis-Filho JS, Kong X, Koya RC, Flaherty KT, Chapman PB, Kim MJ, Hayward R, Martin M, Yang H, Hilton H, Hang JS, Noe J, Lambros M, Geyer F, Dhomen N, Marimuthu A, Nguyen H, Zhan KY, Arts DR, Schlessinger J, Su F, Higgins B, Iyer R, D’Andrea K, Koehler A, Stumm M, Lin PS, Lee RJ, Griggi J, Puzanov I, et al: Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010, 467:598–599.

22. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N: Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia. PNAS 2012, 109:353–359.

23. Rak J, Mitsuhashi Y, Bayko L, Filizus M, Shiitase S, Sazakui T, Kerbel RS: Mutant ras oncoenes upregulate VEGF/VPF expression: Implications for induction and inhibition of tumor angiogenesis. Cancer Res 1995, 55:4753–4780.

doi:10.1186/1477-7819-10-155

Cite this article as: Castellani et al.: Spontaneous splenic rupture in patient with metastatic melanoma treated with vemurafenib. World Journal of Surgical Oncology 2012 10:155.

Submit your manuscript to BioMed Central and take full advantage of:

• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit